Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report

2020 ◽  
Vol 60 ◽  
pp. 319-322
Author(s):  
Jayesh Dhanani ◽  
David A. Pattison ◽  
Matthew Burge ◽  
Julian Williams ◽  
Bernhard Riedel ◽  
...  
2014 ◽  
Vol 71 (9) ◽  
pp. 875-878 ◽  
Author(s):  
Aleksandar Filipovic ◽  
Ljiljana Vuckovic ◽  
Ljubica Pejakov

Introduction. Thyroid paraganglioma is a very rare malignant neuroendocrine tumor. Immunohistochemical features of thyroid paraganglioma are helpful for the diagnosis. Case report. A 69-year-old female came to hospital with the presence of a growing thyroid nodule of the left lobe. Ultrasonic neck examination showed 5 cm hypoechoic nodule in the left thyroid lobe. Thyroid scintigraphy showed a big cold nodule in the left lobe. Computed tomography (CT) scan showed left lobe thyroid tumor with tracheal deviation on the right site. Extended total thyroidectomy was done. Intraoperative consultation with the pathologist confirmed thyroid cancer. The pathologist diagnosed thyroid paraganglioma on the base of immuohistochemical investigation. This thyroid paraganglioma was positive for neuron-specific enolase, chomogranin A, synaptophysin, and S-100 protein highlighted the sustentacular cells. Tumor cells were nega-tive for thyroglobulin, epithelial membrane antigen, cytokeratin, calcitonin, and carcinoembryonic. After the surgery the patient was treated with chemotherapy, peptide receptor radionuclide therapy, and permanent TSH suppressive therapy. The patient was followed with measurements of thyroid hormone and serum neuron-specific enolase, chromogranin A level, every 6 months. Gastroscopy, colonoscopy, chest and abdomen CT scan as well as further tests (chest x-ray, ultrasound of the neck, and whole body octreotide scintigraphy) were done. No primary neuroendocrine tumor in digestive sistem or in the chest was found. After more than 3 years the patient has no evidence of the recurrent disease. Conclusion. Radical resection of thyroid paraganglioma, followed by chemotherapy and peptide receptor radionuclide therapy, should be considered the treatment of choice in patients with thyroid gland paraganglioma.


2014 ◽  
Vol 87 (1-2) ◽  
pp. 92-93 ◽  
Author(s):  
Jennifer Ryan ◽  
Timothy Akhurst ◽  
A. Craig Lynch ◽  
Michael Michael ◽  
Alexander G. Heriot

2021 ◽  
pp. 1-4
Author(s):  
Maria Rinzivillo ◽  
Daniela Prosperi ◽  
Mirco Bartolomei ◽  
Stefano Panareo ◽  
Elsa Iannicelli ◽  
...  

<b><i>Introduction:</i></b> The efficacy of 177Lu-Dotatate was shown in the NETTER-1 trial, an international, open-label, multicentre phase III clinical trial that evaluated the safety and efficacy of 177Lu-Dotatate in patients with well-differentiated, advanced midgut neuroendocrine tumours (NETs) with evidence of disease progression. Recently, retreatment with peptide receptor radionuclide therapy (PRRT) has been proposed as a valid therapeutic option in patients without other effective options who had responded to initial PRRT; however, data on this therapeutic option are still inadequate. <b><i>Case Report:</i></b> In this report, we present the case of a patient who achieved a delayed complete radiological response after initial 177Lu-Dotatate treatment and who had a complete tumour response with PRRT retreatment 5 years later. <b><i>Conclusions:</i></b> This case report shows that, although rare, a complete, prolonged tumour response may occur in patients with advanced small-bowel NETs receiving PRRT. Retreatment with PRRT may be a valid option in cases of subsequent disease recurrence.


2014 ◽  
Vol 16 (suppl 2) ◽  
pp. ii45-ii45
Author(s):  
S. Iglseder ◽  
M. Nowosielski ◽  
A. Muigg ◽  
G. Stockhammer ◽  
C. Freyschlag ◽  
...  

2020 ◽  
Vol 37 (05) ◽  
pp. 499-507
Author(s):  
Evan D. Lehrman ◽  
Nicholas Fidelman

AbstractNeuroendocrine tumor liver metastases are treated by a multidisciplinary cohort of physicians that work together to achieve optimal clinical results for their patients. This review addresses critical concepts in diagnosis and workup of such patients followed by medical, surgical, and liver-directed arterial and ablative therapies. Specific perioperative care for these patients is crucial in avoiding dreaded complications related to Carcinoid Crisis. The recent introduction of Peptide Receptor Radionuclide Therapy as a therapeutic option has impacted some of the algorithms for timing and selection of arterial embolotherapies.


Sign in / Sign up

Export Citation Format

Share Document